10x Genomics (TXG) Return on Capital Employed (2019 - 2026)

10x Genomics (TXG) has 8 years of Return on Capital Employed data on file, last reported at 4.23% in Q1 2026.

• For the quarter ending Q1 2026, Return on Capital Employed rose 1724.0% year-over-year to 4.23%; the trailing twelve-month figure through Mar 2026 stood at 4.23% (up 1724.0% YoY), and the FY2025 full-year result was 7.38%, up 1623.0% from the prior year.
• Return on Capital Employed climbed to 4.23% in Q1 2026, from 6.92% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 4.23% in Q1 2026 to a low of 32.9% in Q1 2024.
• A 5-year average of 19.31% and a median of 19.59% in 2023 frame the typical range for Return on Capital Employed.
• Across the five-year window, Return on Capital Employed soared 5473 bps in 2022 and slumped 1331 bps in 2024, its largest moves.
• Tracing TXG's Return on Capital Employed over 5 years: stood at 19.05% in 2022, then slumped by 68 bps to 31.98% in 2023, then climbed by 25 bps to 24.0% in 2024, then soared by 71 bps to 6.92% in 2025, then jumped by 39 bps to 4.23% in 2026.
• Business Quant data shows TXG's Return on Capital Employed at 4.23% in Q1 2026, 6.92% in Q4 2025, and 10.66% in Q3 2025.